BRIDGEBIO ONCOLOGY THERAPEUTICS INC
BBOT
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
BridgeBio Oncology Therapeutics is a clinical-stage company advancing next-generation small molecule therapeutics targeting RAS and PI3K pathway-driven cancers, launched with $200 million in private capital. Its three lead programs are BBO-8520, a direct KRASG12C inhibitor achieving a 65% objective response rate in NSCLC patients; BBO-11818, a panKRAS inhibitor showing partial responses including a 56% tumor reduction in pancreatic cancer; and BBO-10203, a RAS-PI3Ka breaker. All three programs required preclinical animal testing in tumor xenograft models to establish anti-tumor activity and safety profiles before entering clinical trials. The company holds $425 million in cash as of December 2025, with clinical data updates expected across all programs in the second half of 2026.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.